Cerevel Therapeutics Holdings, Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q1 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q1 2024.
  • Cerevel Therapeutics Holdings, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 120 %, a 47.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 120 +38.4 +47.4% Mar 31, 2024
Q4 2023 125 +66.5 +114% Dec 31, 2023
Q3 2023 132 +93.4 +239% Sep 30, 2023
Q2 2023 106 +85.6 +410% Jun 30, 2023
Q1 2023 81.1 +60.9 +301% Mar 31, 2023
Q4 2022 58.5 +37.9 +184% Dec 31, 2022
Q3 2022 39 +19 +94.6% Sep 30, 2022
Q2 2022 20.9 -2.11 -9.18% Jun 30, 2022
Q1 2022 20.2 +0.65 +3.32% Mar 31, 2022
Q4 2021 20.6 Dec 31, 2021
Q3 2021 20.1 Sep 30, 2021
Q2 2021 23 Jun 30, 2021
Q1 2021 19.6 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.